



Notice of Investment with J.P. Morgan Asset Management's Life Sciences Private Capital

OSAKA, Japan, November 6, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced an investment with J.P. Morgan Life Sciences Private Capital, a group (Administrative office : Luxembourg, Chief Investment Officer: Dr. Stephen Squinto, Ph.D.; hereafter "JPM LSPC") within J.P. Morgan Asset Management.

JPM LSPC is a healthcare investment platform focused on creating and investing in early- and growth-stage life science companies, with a focus on novel therapeutics and technologies. JPM LSPC not only has a highly experienced team, but also an expansive network of academic and industrial connections, established through the decades of experience embodied by their team, which is led by Stephen Squinto, Ph.D.

Through this agreement, Shionogi expects to share its scientific perspective and work with JPM LSPC as they assess emerging scientific trends and a wide range of next-generation biotechnology companies. Through the resulting significant expansion of our global network and perspective, we believe we will be able to strengthen our R&D capabilities and awareness of research "seeds", technologies, and partners around the world, and ensure that our R&D approach is informed by the most advanced strategies applicable to the unmet needs on which we have chosen to focus. Shionogi has invested in the platform with the intent of earning distributions.

Shionogi is committed to "Protect people worldwide from the threat of infectious diseases" and "Improve social productivity and extend healthy lifespan" as our key focus. We are working to achieve total care that goes beyond treating the disease itself to help to bring about a global society characterized by healthy longevity, in which all can enjoy more rewarding lives. Through this agreement, we expect to advance our research and development activities, so that we can develop and provide innovative medicines and other healthcare products to address the unmet needs of patients around the world.

【About J.P. Morgan Life Sciences Private Capital】

J.P. Morgan Life Sciences Private Capital is a healthcare investment platform seeking to promote the discovery and development of clinically important new drugs. The platform supports both early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology. Dr. Stephen Squinto, Ph.D., head of J.P. Morgan Life Sciences Private Capital, is a biotechnology expert, former early company builder at Regeneron Pharmaceuticals and co-founder of Alexion Pharmaceuticals.

【About J.P. Morgan Asset Management】

J.P. Morgan Asset Management, with assets under management of \$2.8 trillion (as of 6/30/2023), is a global leader in investment management. J.P. Morgan Asset Management's clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. J.P. Morgan Asset Management is the marketing name for the asset management businesses of JPMorgan Chase & Co., and its affiliates worldwide.

For more information, please visit www.jpmorganassetmanagement.com

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>